Literature DB >> 23389551

Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Helena Vasconcelos1, Inês Marques, A Rita Santos, Pedro Melo, Isabel Pires, João Figueira, José Faria de Abreu, M Luz Cachulo, Rufino Silva.   

Abstract

PURPOSE: To evaluate morphological and functional chorioretinal changes 5 years after standard photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC).
METHODS: A retrospective, nonrandomized study, including patients with chronic CSC treated with standard PDT and followed for at least 60 months. All patients underwent a complete ophthalmological examination, and the location and number of treatments were registered. Five or more years after treatment, subfoveal and non-subfoveal treated areas were evaluated with Spectralis optical coherence tomography and microperimetry.
RESULTS: Seventeen eyes of 15 patients were included, with mean age of 48.3 ± 8.4 years and a mean follow-up of 80.6 ± 12.4 months (range from 62 to 104 months). All eyes had neurosensory detachment (NSD) at baseline. Treatment was performed under the fovea in 58.8 % and in a non-foveal area in 41.2 % of the eyes. At the final visit all eyes had resolution of the NSD, with a statistical significant reduction in central macular thickness (p = 0.005) and preserved neuroretinal thickness (p = 0.839). There was a statistical difference between initial and final BCVA (p < 0.001) and a mean gain of 8.4 ± 7.8 letters. Subfoveal morphological changes in external limiting membrane (ELM) and in photoreceptor inner and outer segment junction (IS/OS) were correlated with final BCVA (p = 0.015 and p = 0.014 respectively), but not with the variation of BCVA. There was a statistical correlation between morphological changes in IS/OS line and retinal sensitivity in the central 12° and 2° (p = 0.003 and p = 0.002 respectively). The morphological changes in the subfoveal layers were not dependent on treatment location (p = 0.154, p = 0.644, and p = 1.0 for ELM, IS/OS line, and retinal pigment epithelium respectively). Subfoveal final mean choroidal thickness was 295.1 ± 68.7 μm, and showed no statistical difference from the normal population (p = 0.633).
CONCLUSIONS: Morphological and functional chorioretinal changes, observed 5 or more years after standard PDT for chronic CSC, were not correlated with the location of treatment, neither with the progression of visual acuity or with the location of treatment, and are more likely to be related to the disease itself than with the treatment provided.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23389551     DOI: 10.1007/s00417-013-2270-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  42 in total

1.  Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy.

Authors:  Arif Koytak; Kazim Erol; Erol Coskun; Nihal Asik; Hakan Öztürk; Yusuf Özertürk
Journal:  Retina       Date:  2010 Nov-Dec       Impact factor: 4.256

2.  Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.

Authors:  Kyoko Fujita; Mitsuko Yuzawa; Ryusaburou Mori
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

3.  The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy.

Authors:  Felice Cardillo Piccolino; Roberta Rigault de la Longrais; Giambattista Ravera; Chiara M Eandi; Luca Ventre; Ali' Abdollahi; Marilisa Manea
Journal:  Am J Ophthalmol       Date:  2005-01       Impact factor: 5.258

4.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

5.  Macular sensitivity in eyes with central serous chorioretinopathy.

Authors:  H Ozdemir; F Senturk; M Karacorlu; S Arf Karacorlu; O Uysal
Journal:  Eur J Ophthalmol       Date:  2008 Sep-Oct       Impact factor: 2.597

6.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

7.  Vascular targeting in photodynamic occlusion of subretinal vessels.

Authors:  U Schmidt-Erfurth; T Hasan; E Gragoudas; N Michaud; T J Flotte; R Birngruber
Journal:  Ophthalmology       Date:  1994-12       Impact factor: 12.079

8.  Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; David T L Liu; Dennis S C Lam
Journal:  Ophthalmology       Date:  2008-06-05       Impact factor: 12.079

9.  Digital indocyanine green videoangiography of central serous chorioretinopathy.

Authors:  D R Guyer; L A Yannuzzi; J S Slakter; J A Sorenson; A Ho; D Orlock
Journal:  Arch Ophthalmol       Date:  1994-08

10.  Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study.

Authors:  Wai-Man Chan; Timothy Y Y Lai; Ricky Y K Lai; Emily W H Tang; David T L Liu; Dennis S C Lam
Journal:  Retina       Date:  2008-01       Impact factor: 4.256

View more
  22 in total

1.  Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.

Authors:  Andrea Russo; Raffaele Turano; Francesco Morescalchi; Elena Gambicorti; Anna Cancarini; Sarah Duse; Ciro Costagliola; Francesco Semeraro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-10       Impact factor: 3.117

2.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

3.  Retinal sensitivity assessed by microperimetry and corresponding retinal structure and thickness in resolved central serous chorioretinopathy.

Authors:  H W Chung; C M Yun; J T Kim; S-W Kim; J Oh; K Huh
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

4.  Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy.

Authors:  Ayako Yasui; Manabu Yamamoto; Kumiko Hirayama; Kunihiko Shiraki; Dirk Theisen-Kunde; Ralf Brinkmann; Yoko Miura; Takeya Kohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-06       Impact factor: 3.117

Review 5.  [Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

Authors: 
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

6.  Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy.

Authors:  Cyprian Gabriel Ntomoka; Bindu Rajesh; Gachago Muchai Muriithi; Abhilash Goud; Jay Chhablani
Journal:  Eye (Lond)       Date:  2018-02-12       Impact factor: 3.775

7.  Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.

Authors:  Yong-Kyu Kim; Na-Kyung Ryoo; Se Joon Woo; Kyu Hyung Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-24       Impact factor: 3.117

Review 8.  [Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on central serous chorioretinopathy : Status 18 October 2021].

Authors: 
Journal:  Ophthalmologe       Date:  2021-12-14       Impact factor: 1.059

9.  Structural and Functional Outcomes in Chronic Central Serous Chorioretinopathy Treated with Photodynamic Therapy.

Authors:  Pino Cidad; Eugenia González; Mónica Asencio; Jesús García
Journal:  Korean J Ophthalmol       Date:  2015-09-22

10.  Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy.

Authors:  Yong-Il Shin; Kyeung-Min Kim; Min-Woo Lee; Jung-Yeul Kim; Young-Joon Jo
Journal:  Jpn J Ophthalmol       Date:  2019-12-20       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.